CX3CR1 Deficiency Exacerbates Immune-mediated Hepatitis by Increasing NF-κB-mediated Cytokine Production in Macrophage and T Cell
Overview
Authors
Affiliations
Immune-mediated hepatitis is marked by liver inflammation characterized by immune cell infiltration, chemokine/cytokine production, and hepatocyte injury. C-X3C motif receptor 1 (CX3CR1), as the receptor of chemokine C-X3C motif ligand 1 (CX3CL1)/fractalkine, is mainly expressed on immune cells including monocytes and T cells. Previous studies have shown that CX3CR1 protects against liver fibrosis, but the exact role of CX3CL1/CX3CR1 in acute immune-mediated hepatitis remains unknown. Here, we investigate the role of the CX3CL1/CX3CR1 axis in immune-mediated hepatitis using concanavalin A (ConA)-induced liver injury model in CX3CR1-deficient ) mice. We observed that mice had severe liver injury and increased pro-inflammatory cytokines (tumor necrosis factor-alpha [TNF-α], interferon-gamma [IFN-γ], interleukin-1 beta [IL-1β], and IL-6) in serum and liver compared to wild-type () mice after ConA injection. The deficiency of CX3CR1 did not affect ConA-induced immune cell infiltration in liver but led to elevated production of TNF-α in macrophages as well as IFN-γ in T cells after ConA treatment. On the contrary, exogenous CX3CL1 attenuated ConA-induced cytokine production in wild type, but not CX3CR1-deficient macrophages and T cells. Furthermore, results showed that CX3CR1 deficiency promoted the pro-inflammatory cytokine expression by increasing the phosphorylation of nuclear factor kappa B (NF-κB) p65 (p-NF-κB p65). Finally, pre-treatment of p-NF-κB p65 inhibitor, resveratrol, attenuated ConA-induced liver injury and inflammatory responses, especially in mice. In conclusion, our data show that the deficiency of CX3CR1 promotes pro-inflammatory cytokine production in macrophages and T cells by enhancing the phosphorylation of NF-κB p65, which exacerbates liver injury in ConA-induced hepatitis.
Yang Z, Liu M, Chang Z, Du C, Yang Y, Zhang C Front Immunol. 2024; 15:1465938.
PMID: 39497829 PMC: 11532040. DOI: 10.3389/fimmu.2024.1465938.
CX3CL1 (Fractalkine)-CX3CR1 Axis in Inflammation-Induced Angiogenesis and Tumorigenesis.
Szukiewicz D Int J Mol Sci. 2024; 25(9).
PMID: 38731899 PMC: 11083509. DOI: 10.3390/ijms25094679.
Meng C, Liu Y, Ming Y, Lu C, Li Y, Zhang Y Pharmaceutics. 2024; 16(1).
PMID: 38258120 PMC: 10818704. DOI: 10.3390/pharmaceutics16010110.
Stakisaitis D, Kapocius L, Kilimaite E, Gecys D, Slekiene L, Balnyte I Pharmaceutics. 2023; 15(12).
PMID: 38140056 PMC: 10747708. DOI: 10.3390/pharmaceutics15122715.